Hudson Technologies, Inc. (HDSN)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-29
$4.31-2.49%
Close 2026-10-30 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-29
Research Workspace
Put HDSN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 52% in its worst 12-month stretch.
View RiskHDSN’s partnership-led growth and refrigerant recycling need to translate into stronger earnings. Revenue grew 8% year over year in Q2, while Q3 GAAP EPS missed consensus by 54.5%. It trades at 16× P/E versus the peer median of 17×. The price reflects less growth than our forecast, despite the latest earnings miss. A 33% next-quarter miss probability and weak execution quality threaten that case. Peer multiples imply a price about 33% above where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. HDSN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering HDSN (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare HDSN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HDSN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put HDSN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain full-year 2026 gross margin in the low-to-mid-twenties
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Reaffirms the 2026 margin objective and cites progress on strategic partnership and DLA contract.
Advances: Expand strategic growth via M&A and partnerships
Icorium deal supports strategic growth via partnerships.
Threatens: Drive revenue growth and operational excellence
Volume growth not translating to bottom line impacts revenue growth.
Advances: Expand strategic growth via M&A and partnerships
Strategic partnership aligns with growth objectives.
Advances: Manage capital allocation
Management buying shares indicates confidence in capital allocation.